NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

PET Imaging of Neuroinflammation in Neurodegenerative Diseases via a Novel TSPO Radioligand

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

19-M-0095

Sponsoring Institute

National Institute of Mental Health (NIMH)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Fetuses;
Neonates;
Pregnant Women;
Children

Keywords

Fronto Temporal Dementia;
Amyloid;
Neuroinflammation

Recruitment Keyword(s)

None

Condition(s)

Dementia

Investigational Drug(s)

11C-PIB
11C-ER176

Investigational Device(s)

None

Intervention(s)

Drug: 11C-ER176
Drug: 11C-PIB

Supporting Site

National Institute of Mental Health

Background:

Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved. Researchers want to see if scans using radioactive drugs can show brain inflammation.

Objective:

To see if the drug [11C]ER176 can show inflammation in the brain in people with certain progressive neurological disorders compared to healthy adults. Also to find genes that might be associated with or cause these disorders.

Eligibility:

People ages 18 and older with an aging-related neurological disorder, and healthy adults

Design:

Participants will be screened with a medical history, physical exam, neurological exam, psychiatric history, and blood tests.

Participants will have 2-5 visits for the first session. They will have 2 PET scans and 1 MRI scan. They may have 3 more sessions: 6 months to about 18 months later, 1 year after that, and about 30 months to 5 years after the first visit. There may be up to 20 total visits.

For the scans, participants will lie on a bed that slides into the scanners. For the PET scans, a strap will fix their head in place. A radioactive drug will be injected through a catheter. A needle will guide a thin plastic tube into an arm vein. Additional catheters may be put in place to draw blood. Each PET will take 2 hours. The MRI will take 30 60 minutes.

At each session, participants will have a brief interview, medical history, physical exam, blood and urine tests, heart tests, and memory and thinking tests. They may donate blood for DNA tests.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

1. Patients will be included if they

-Are age 18 or older

--Have the ability to understand and sign an informed consent, or have a DPA or a court-appointed guardian (or be able to understand the DPA process to appoint a DPA) to provide consent for adults without consent capacity

--Have been given a diagnosis by a neurologist of frontotemporal dementia, frontotemporal lobar degeneration, primary progressive aphasia, semantic dementia, motor neuron disorder, amyotrophic lateral sclerosis, primary lateral sclerosis, progressive bulbar palsy, corticobasal syndrome, Huntington disease, Alzheimer s disease, or other related adult-onset neurodegenerative disease

2. Subjects with an increased risk of neurodegenerative diseases will be included if they

--Are age 18 or older

--Are able to give written informed consent

--Have known family history or other risk of an adult-onset genetic neurodegenerative disease, and/or mutation in a gene known to cause an adult-onset neurodegenerative disease

3. Healthy subjects will be included if they

--Are age 18 or older

--Are willing and able to complete all study procedures

--Are able to give written informed consent

--Are medically healthy

--Are enrolled in 01-M-0254 The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers (PI: Dr. Carlos Zarate) or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies (PI: Dr. Joyce Chung)

EXCLUSION CRITERIA:

1. Patients or subjects with an increased risk of neurodegenerative diseases will be excluded if they

-Have other major neurological or medical diseases that may cause progressive weakness or cognitive dysfunction, such as structural brain or spinal cord disease, metabolic diseases, paraneoplastic syndromes, infectious diseases, peripheral neuropathy or radiculopathy or other significant neurological abnormalities

-Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., active infection or untreated malignancy)

-Require daytime ventilator support at the time of study entry

-Are unable to travel to NIH

-Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits

-Have inability to lie flat and/or lie still on camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with patient and/or caregiver during the screening visit

-Are pregnant or breastfeeding

-Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function

-Are unable to have an MRI scan (e.g., pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments in the eye)

-NIMH employees/staffs or NIH employees who are subordinates/relatives/co-workers of investigators

2. Healthy subjects will be excluded if they

-Have any history of medical illness or injury with the potential to affect study data interpretation or to be any medical contraindication to the procedures performed in the study, including active infection and untreated malignancy.

-Have clinically significant laboratory abnormalities based on test performed under screening protocol 01-M-0254 or 17-M-0181

-Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits

-Have inability to lie flat on camera bed for at least two hours, including claustrophobia and overweight greater than the maximum for the scanner

-Are pregnant or breastfeeding

-Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function

-Are unable to have an MRI scan (e.g., pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments in the eye)

-NIMH employees/staffs or NIH employees who are subordinates/relatives/co-workers of investigators


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Robert B. Innis, M.D.
National Institute of Mental Health (NIMH)
NIHBC 10 - CLINICAL CENTER BG RM B1D43J
10 CENTER DR
BETHESDA MD 20892
(301) 594-1368
robert.innis@nih.gov

Maria D. Ferraris Araneta, C.R.N.P.
National Institute of Mental Health (NIMH)
NIHBC 10 - CLINICAL CENTER BG RM B1D43G
10 CENTER DR
BETHESDA MD 20892
(301) 496-9423
ferrarism@mail.nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1
ccopr@nih.gov

Clinical Trials Number:

NCT03958630

--Back to Top--